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Background.Management of thyroid nodules with benign aspirates following atypia of undetermined significance/follicular lesion
of undetermined significance (AUS/FLUS) is not well established. We reviewed the risk of malignancy and the role of ultrasound
(US) features among thyroid nodules with benign results following initial AUS/FLUS diagnoses.Methods. FromDecember 2009 to
February 2011, a total of 114 nodules in 114 patients diagnosed as benign on follow-up fine-needle aspiration (FNA) after AUS/FLUS
results were included in our study. Eight among 114 nodules were confirmed pathologically and 106 were clinically observed by
a follow-up FNA or US. Suspicious US features were defined as markedly hypoechogenicity, irregular or microlobulated margin,
presence of microcalcifications, and taller than wide shape. Results.There were 110 (96.5%) benign nodules and 4 (3.5%) malignant
nodules. Two (4.8%) among 42 nodules without suspicious US features and 2 (2.8%) out of 72 nodules with suspicious US features
were confirmed as malignancy, but there were no significant associations between themalignancy rate and US features (𝑃 = 0.625).
Conclusion. Clinical follow-up instead of surgical excision or continuous repeat FNA may be enough for benign thyroid nodules
after AUS/FLUS. The role of US features might be insignificant in the management of these nodules.
1. Introduction
Fine-needle aspiration (FNA) is a useful test for thyroid
nodule evaluation and has been widely accepted as the
main diagnostic procedure [1–3]. In the past, no uniform
criteria were established for the various diagnostic categories
and diagnostic inconsistencies, a reason for difficulty in
communicating the clinical implications of thyroid FNA
results [4–6]. Fortunately, a uniform classification scheme
was proposedwith 6 distinct diagnostic categories in the 2007
National Cancer Institute Thyroid Fine Needle Aspiration
State of the Science Conference and led to the subsequent
Bethesda system for ReportingThyroid Cytopathology [3, 7–
9].
According to the Bethesda system, atypia of undeter-
mined significance/follicular lesion of undetermined signif-
icance (AUS/FLUS) is a heterogeneous category. The risk
of malignancy for all AUS/FLUS cases, including those
patients with benign follow-up and in whom surgery was not
performed, presumably is up to 5–15% and the recommenda-
tion for AUS/FLUS is repeat FNA follow-ups at appropriate
intervals [8, 10]. Faquin and Baloch reported that no case was
finally confirmed as malignancy among nodules with initial
AUS/FLUS cytology results and benign results in repeat FNA
[11]. They regarded repeat FNA as an effective means for
definitive management-based diagnosis [11]. On the other
hand, the rate of malignant diagnosis in patients with benign
cytology results after an initial AUS/FLUS diagnosis was said
to be 29% or 15%, in other studies, respectively [12, 13].
Since the risk of malignancy in patients with benign aspirates
following an initial AUS/FLUS seems to remain higher than
that of patients with a benign diagnosis alone, treating these
patients in a equivalent manner is disputable and approaches
to further management are not well established [12, 13].
In a recent study on thyroid nodules diagnosed as
AUS/FLUS, the risk of malignancy was different accord-
ing to ultrasound (US) findings, which provided ancillary
information for patients with AUS/FLUS [14–16]. However,
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to our knowledge, the US features of nodules with benign
results following initial AUS/FLUS cytology have not been
examined. Therefore, in this study we reviewed the risk
of malignancy and the role of US features among thyroid
nodules with benign results following initial AUS/FLUS
diagnoses.
2. Materials and Methods
2.1. Patients. Institutional review board approval was obtain-
ed and informed consent was waived for this retrospective
study. Written informed consent was obtained from all
patients for US-guided FNA prior to each procedure as part
of daily clinical practice.
From December 2009 to Feburuary 2011, a total of
6450 consecutive patients underwent US-guided FNA for
7954 thyroid nodules in our institution and reported as
follows according to the Bethesda system: nondiagnostic or
unsatisfactory (𝑛 = 1270, 16.0%), benign (𝑛 = 4664, 58.6%),
atypia of undetermined significance or follicular lesion of
undetermined significance (𝑛 = 415, 5.2%), follicular neo-
plasm or suspicious for follicular neoplasm (𝑛 = 63, 0.8%),
suspicious for malignancy (𝑛 = 404, 5.1%), and malignant
(𝑛 = 1138, 14.3%). Among 7954 nodules, 415 nodules (5.2%)
in 384 patients were reported as AUS/FLUS. Of these, 121
nodules in 121 patients were diagnosed as benign on follow-
up FNA. Among them, 43 nodules were excluded for the
following reasons: no further follow-up including a second
US-guided FNA or follow-up US after more than 1 year or
no surgery (𝑛 = 39) and no advanced management such
as surgery or additional FNA despite increased nodule size
being noted on follow-up US (𝑛 = 4). A total of 78 nodules
in 78 patients were included in this study. During the same
period, based on the review of FNA slides by the pathology
department of our institution, 240 nodules in 238 patients
who had undergone US-guided FNA in outside clinics were
classified as AUS/FLUS. Among them, 50 nodules in 49
patients were diagnosed as benign on follow-up US-guided
FNA in our institution. Fourteen of 50 nodules without
further follow-up (𝑛 = 13) and without additional work-
up despite increase in size on follow-up US (𝑛 = 1) were
excluded from this study. A total of 36 nodules in 36 patients
with initial FNA done in outside hospitals were included in
our study sample. Altogether, a total of 114 nodules in 114
patients were finally included in our study (Figure 1).
Of 114 nodules, 8 nodules were confirmed pathologically
and 106 nodules were clinically observed by a third follow-
up FNA (𝑛 = 17) or follow-up US after more than 1 year
(𝑛 = 89). Surgery was performed in the patients for the
following reasons: known papillary thyroid carcinoma in the
other thyroid gland (𝑛 = 3), compression symptoms or
cosmetic problems due to large goiter (𝑛 = 3), positive
BRAFV600E mutation on follow-up FNA (𝑛 = 2), patient’s
request to undergo surgery (𝑛 = 1), and a 3rd FNA which
was “suspicious for papillary thyroid carcinoma” (𝑛 = 1). The
mean period of follow-up US was 22.6 months (range, 12.0–
36.4 months; median, 22.1 months).The 89 nodules observed
by follow-upUS showeddecrease in size (𝑛 = 9) or no interval
change in size (𝑛 = 80) on their follow-up US after more than
1 year.
2.2. US Exams, US-Guided FNA, and Cytologic Analysis.
A 5–12MHz linear probe (iU22, Philips Medical Systems,
Bothell,WA) or a 6–13MHz linear probe (EUB-7500, Hitachi
Medical, Tokyo, Japan) was used for thyroid gland evaluation.
Twelve board-certified radiologists specialized in thyroid
imaging with 1–16 years of experience performed US and
subsequent US-guided FNA. Markedly hypoechogenicity,
irregular or microlobulated margin, presence of microcal-
cifications, and taller than wide shape were regarded as
suspicious US features [17]. Size (the longest diameter of the
nodule) and location (right or left thyroid gland and upper,
mid, lower pole of thyroid gland) were also recorded.
US-guided FNA was performed by the same radiologist
who performed the US. Each nodule was aspirated at least
twice using the freehand technique with a 23-gauge needle
connected with a 2-mL disposable plastic syringe. The spec-
imen was expelled on a glass slide and then immediately
placed in 95% alcohol for Papanicolaou staining [14, 18]. On-
site evaluation was not performed in our institution. The
Bethesda classifications were used in the cytology reports of
thyroid aspirates.
2.3. Data and Statistical Analysis. We regarded cytopatho-
logical results as the “gold standard” and classified the
cytopathological results as follows: cytopathologically con-
firmed malignancies were classified into the positive group
and cytopathologically confirmed or clinical benign nodules
through follow-up US were classified into the negative group.
Comparisons of frequency distributions for categorical vari-
ables were performed by Fisher’s exact test. Independent two-
sample t-tests were used to compare continuous variables
between benign and malignant nodules.
Analysis was performed using SPSS statistical software
(SPSS Inc., Chicago, IL, ver 20.0), and statistical significance
was accepted with 𝑃 values <0.05.
3. Results
A total of 114 nodules from 114 patients (97 women, 17
men) were included. There were 110 (96.5%) benign nodules
and 4 (3.5%) malignant nodules. The mean patient age was
49.9 ± 12.4 years (range, 17–77 years). The mean size of
the 114 nodules was 13.5 ± 10.9mm (range, 3–51mm). The
benign nodules were smaller than the malignant nodules,
but without any statistical significance (𝑃 = 0.771, Table 1).
There were no significant associations between the risk of
malignancy and other baseline characteristics of nodules
according to cytopathological outcomes (Table 1).
US features of the 114 nodules are summarized in Table 2.
Among the 114 nodules, 72 (63.2%) had no suspicious US
features mentioned above whereas 42 (36.8%) showed one or
more suspicious US features. Of the 72 nodules without sus-
picious US features, 2 (2.8%) were pathologically confirmed
as malignancy. Of 42 nodules with suspicious US features, 2
(4.8%)were confirmed asmalignancy.Therewas no statistical
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Figure 1: Flowchart of study population selection. FNA: fine needle aspiration; AUS/FLUS: atypia of undetermined significance/follicular
lesion of undetermined significance.
significant difference (𝑃 = 0.625). Four malignant nodules
with benign aspirates following initial AUS/FLUS findings
were pathologically confirmed by surgery (papillary thyroid
carcinoma (𝑛 = 2), follicular variant papillary thyroid
carcinom (𝑛 = 1), and follicular carcinoma (𝑛 = 1))
(Table 3; Figures 2 and 3). All 4 patients were confirmed with
euthyroid status without thyroid autoantibodies. Among the
110 nodules diagnosed as benign, four were pathologically
confirmed as benign by surgery (adenomatous hyperplasia
(𝑛 = 2) and follicular adenoma (𝑛 = 2)). The other 106
nodules were clinically observed by follow-up FNA (𝑛 =
17) or follow-up US (𝑛 = 89). Out of 17 nodules with
benign follow-up aspirates, 15 nodules were reported as
benign follicular nodules and 2 nodules were lymphocytic
thyroiditis.
4. Discussion
The rate of AUS/FLUS has varied from 1.2% to 17.8% although
the Bethesda system limits its designation to approximately
7% or fewer of all thyroid FNAs and an effort should be
made to assign this category as little as possible [8, 19–
23]. The appropriate management of AUS/FLUS is a great
challenge as the category describes a wide variety of scenarios
due to lack of strict cytological morphologic criteria. Even
though surgery might definitively resolve clinical uncer-
tainty, unnecessary surgery should be avoided when possible
considering that most patients have been proven to have
benign diseases [2, 24]. Before the Bethesda system, thyroid
lesions which did not fit into the benign or malignant
category were placed into an “indeterminate” category [25].
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Table 1: Demographic and baseline characteristics in 114 patients
with 114 thyroid nodules with benign aspirates following initial
AUS/FLUS.
Characteristics Standard reference 𝑃 value
Benign
(𝑛 = 110)
Malignant
(𝑛 = 4)
Gender >0.999
Male 17 (15.5%) 0
Female 93 (84.5%) 4 (100%)
Age (years) 49.9 49.0 0.900
Size (mm) 13.5 16.0 0.797
Location 0.304
Right 66 (60.0%) 1 (25.0%)
Left 44 (40.0%) 3 (75.0%)
Location 0.074
Upper pole 23 (20.9%) 0
Mid pole 45 (40.9%) 4 (100%)
Lower pole 42 (38.2%) 0
Underlying thyroid
echogenicity 0.195
Homogenous 88 (80.0%) 2 (50.0%)
Heterogenous 22 (20.0%) 2 (50.0%)
Multiplicity 0.630
Single 49 (44.5%) 1 (25.0%)
Multiple 61 (55.5%) 3 (75.0%)
AUS/FLUS: atypia of undetermined significance/follicular lesion of undeter-
mined significance.
Most patients with this category were referred for diagnostic
surgery, but the majority proved to have benign disease,
which meant that unnecessary surgeries had been mostly
performed [24, 26]. After the indeterminate categorywas split
by the Bethesda system, repeat FNA in patients diagnosed
as AUS/FLUS clearly allowed better selection of patients
needing surgical excision [11, 27, 28]. Patients with repeat
FNA after AUS/FLUS diagnosis underwent surgical excision
more frequently than patients without repeat FNA after
AUS/FLUS diagnosis and the malignancy rate on surgical
excision was also different between the two groups [11].
Moreover, because many malignancies diagnosed after an
AUS/FLUS aspiration are well-differentiated tumors with
little chance of progression and as a large majority of thyroid
cancers show indolent behavior, surgery might as well be
reserved for therapeutic purposes [13, 29–32].
The recommended approach to initial AUS/FLUS is
repeat FNA which can result in a more definitive diagnosis
for about 80% of the nodules based on the Bethesda system
[8, 23]. However, it is controversial whether a thyroid nodule
with a benign result on repeat FNAafterAUS/FLUS diagnosis
should be conservatively managed like a thyroid nodule
with benign cytology alone [11, 18]. The malignancy risk
of a benign aspirate after an initial AUS/FLUS diagnosis
is higher than 15% in some studies [12, 13]. On the other
hand, in some studies, the malignancy rate in nodules with
Table 2: Ultrasound features of 114 lesions.
US features Standard reference 𝑃 value
Benign
(𝑛 = 110)
Malignancy
(𝑛 = 4)
Composition 0.412
Solid 97 (88.2%) 3 (75.0%)
Mixed, solid < 50% 5 (4.5%) 0
Mixed, solid > 50% 8 (7.3%) 1 (25.0%)
Echogenicity 0.472
Hyperechogenicity 2 (1.8%) 0
Isoechogenicity 44 (40.0%) 3 (75.0%)
Hypoechogenicity 59 (53.6%) 1 (25.0%)
Markedly
hypoechogenicity 5 (4.5%) 0
Margin >0.999
Well-defined 66 (60.0%) 3 (75.0%)
Microlobulated 37 (33.6%) 1 (25.0%)
Irregular 7 (6.4%) 0
Calcifications 0.562
Microcalcifications 11 (10.0%) 1 (25.0%)
Macrocalcifications 9 (8.2%) 0
No calcification 90 (81.8%) 3 (75.0%)
Shape 0.436
Wider than tall 96 (87.3%) 3 (75.0%)
Taller than wide 14 (12.7 %) 1 (25.0%)
Vascularity >0.999
Peripheral 38 (34.5%) 2 (50.0%)
Central 1 (0.9%) 0
Both peripheral
and central 39 (35.5%) 1 (25.0%)
No vascularity 32 (29.1%) 1 (25.0%)
US assessment 0.625
Without suspicious
US features 70 (63.6%) 2 (50.0%)
With one or more
suspicious US features 40 (36.4%) 2 (50.0%)
a benign aspirate after an initial AUS/FLUS diagnosis was
much lower than 3% which is even lower than the assumed
malignancy rate of the benign category in the Bethesda
system [11, 27]. This variability in the reported malignancy
rates of AUS/FLUS reflects the subjectivity and heterogeneity
of this category [33, 34]. In this study, we demonstrated that
4 (3.5%) out of 114 nodules with benign aspirates following
initial AUS/FLUS were diagnosed as malignant nodules.
This malignancy rate of 3.5% is similar to that for patients
diagnosed as benign according to the Bethesda system for
thyroid cytopathology (assumedmalignancy rate in the 0–3%
range) for whom clinical follow-up is typically recommended
as the usual management [8]. Accordingly, it is evident that
clinical and radiological follow-up instead of early surgical
intervention can be suggested carefully in the nodules with
benign aspirates following initial AUS/FLUS results in view
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(a)
(b)
Figure 2: A 54-year-old woman diagnosed with papillary thyroid
carcinoma. A 7 mm hypoechogenic nodule with a benign aspirate
following an initial atypia of undetermined significance/follicular
lesion of undetermined significance finding shows microlobulated
margin and mixed calcifications on transverse US scan (a) and
longitudinal US scan (b).
of the presented results of our study as well as other previous
studies [11, 27, 28].
US features of thyroid nodules with AUS/FLUS will help
differentiate malignancy. Although AUS/FLUS nodules with-
out suspicious US features cannot bemanaged conservatively
exactly like benign nodules, nodules with suspicious US
features showed a high malignancy rate ranging from 41.7%
to 100%, leading to direct surgery without treatment delay
[14–16]. Even nodules having the same FNA results revealed
different malignancy rates depending on their US features
[35].We intended to discover the role ofUS features of benign
aspirate results after an initial AUS/FLUS or predictive US
features for malignancy in nodules with benign results after
AUS/FLUS cytology. There were no significant differences
in clinical characters or US features between malignant and
benign nodules: half of the 4 nodules confirmed as cancer had
no suspicious US features and the other 2 nodules showed
suspicious US features.
Our study has several limitations. First, our sample size is
relatively small; therefore, a further study with a large sample
size is needed to establish the most appropriate management
and find occult clinical implications of US findings in this
group. Second, not all nodules were confirmed through
surgery, but this limitation may be inevitable because not all
thyroid nodules detected on US undergo surgery in clinical
practice. Third, the statistical power about the differentiation
(a)
(b)
Figure 3: A 54-year-old woman diagnosed with follicular variant
papillary thyroid carcinoma. A 43 mm isoechogenic mass with
a benign aspirate following an initial atypia of undetermined
significance/follicular lesion of undetermined significance finding
shows no suspicious US features on transverse US scan (a) and
longitudinal US scan (b).
of US features according to malignancy in the study sample
may be compromised because the number of cases confirmed
as malignancy in our study was too small. Fourth, inter-
observer and intraobserver variability was not considered
when US findings of thyroid nodules were assessed or when
cytological results were found as AUS/FLUS. However, in
previously published studies, experienced radiologists per-
forming US guided FNA in our institution have shown
substantial agreement usingCohen’s kappa statistics and their
final assessments have been proven to be highly accurate [36].
In conclusion, our study suggests that benign aspirates on
follow-up FNA in patients with initial AUS/FLUS diagnoses
may be enough to recommend clinical follow-up instead of
surgical excision or continuous repeat FNA. The role of US
features was insignificant in the management of this group,
but further studies with larger samples are required.
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